Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer.

PHASE1UnknownINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 7, 2020

Primary Completion Date

December 31, 2020

Study Completion Date

March 31, 2021

Conditions
Advanced Pancreatic Cancer
Interventions
DRUG

Irinotecan Liposome Injection combined with 5-FU/LV

Drug: Irinotecan Liposome Injection 70mg/m2 (CSPC) combined with 5-FU/LV; Drug: Irinotecan Liposome Injection 70mg/m2 (Ipsen, ONIVYDETM) combined with 5-FU/LV;

Trial Locations (1)

300060

RECRUITING

Tianjin Cancer Hospital, Tianjin

All Listed Sponsors
lead

CSPC Ouyi Pharmaceutical Co., Ltd.

INDUSTRY

NCT04482257 - Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer. | Biotech Hunter | Biotech Hunter